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High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term
remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the
safety and efﬁcacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining
outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December
2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT,
hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the
time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large
B cell lymphoma (n ¼ 73, 37%) or mantle cell lymphoma (n ¼ 69, 34%). One hundred and ﬁfteen patients (57%)
had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years)
for survivors, PFS and OS at 3 years were 60% (95% conﬁdence interval [CI], 53% to 68%) and 73% (95% CI, 67%
to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after
HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with
TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a
median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL
undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of
historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in
elderly patients.
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High-dose therapy and autologous stem cell trans-
plantation (HDT-ASCT) has been widely used as con-
solidative therapy in upfront or salvage settings across a
range of non-Hodgkin lymphoma (NHL) histologies. The
multicenter prospective randomized phase III Parma trial
established HDT-ASCT as a standard-of-care in relapsed or
refractory intermediate or high-grade NHL chemosensitiveedgments on page 2008.
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ty for Blood and Marrow Transplantation.vival (OS) and progression-free survival (PFS) beneﬁt [1].
Similarly, the multicenter, randomized phase III CUP trial
established PFS and OS beneﬁt for early relapsed or re-
fractory follicular lymphoma (FL) patients randomly assigned
to HDT-ASCTcompared with further chemotherapy alone [2].
In mantle cell lymphoma (MCL), the prospective randomized
trial of the European MCL Network, as well as the Nordic
Lymphoma GroupMCL2 study, established HDT-ASCT as part
of ﬁrst-line therapy demonstrating long term PFS with
HDT-ASCT in ﬁrst remission [3-5]. Prognosis is generally poor
in T cell lymphoma (TCL) because of low response rates and
less durable remissions to conventional chemotherapy.
Several retrospective and prospective studies have reported
Table 1
Patient Characteristics Overall (n ¼ 202)
Characteristic Value
Age at transplantation, median (range), yr 65 (60-74)
Gender (male) 136 (67%)
Histology, n
DLBCL 74 (37%)
CR1, n 3
CR2, n 49
CR3 or more, n 4
PR, n 18
MCL 69 (34%)
CR1, n 61
CR2, n 4
PR, n 4
FL 12 (6%)
CNSL 13 (7%)
TCL 25 (12%)
Other NHL 9 (4%)
Conditioning
BEAM 149 (74%)
Rituximab-BEAM 10 (5%)
RIT-BEAM 12 (6%)
Other 31 (15%)
Transplantations in ﬁrst remission 93 (46%)
HCT-CI
Low (0) 42 (21%)
Intermediate (1-2) 45 (22%)
High (>2) 115 (57%)
DLBCL indicates diffuse large B-cell lymphoma;MCL, mantle cell lymphoma;
FL, follicular lymphoma; CNSL, central nervous system lymphoma; TCL, T-
cell lymphoma; NHL, Non-Hodgkin lymphoma; CR, complete remission; PR,
partial remission; RIT, radio-immunotherapy; HCT-CI, hematopoietic stem
cell transplant comorbidity index; BEAM, carmustine, etoposide, cytarabine,
melphalan.
Data presented are n (%) unless otherwise indicated.
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 2004e2009 2005encouraging results with HDT-ASCT as ﬁrst-line consolida-
tion option [6-9]. The National Comprehensive Cancer
Network recommends consideration of HDT-ASCT for most
TCL in ﬁrst complete remission [10].
Although themajority of patients diagnosed with NHL are
older than 60 years, most studies of HDT-ASCT for lymphoma
have been performed on patients younger than 60 years.
Therefore, safety and efﬁcacy of HDT-ASCT is not well
established in this age group. Given the limited information
on feasibility of HDT-ASCT in elderly [11-18], we retrospec-
tively evaluated the outcomes of HDT-ASCT in 202 NHL
patients ages 60 years and older at our institution over the
11-year period from January 2001 to December 2012. The
aim of this study was to determine tolerability and efﬁcacy of
HDT-ASCT in elderly patients with varied comorbidities, to-
ward the goal of clarifying eligibility for this procedure.
PATIENTS AND METHODS
Patient and Graft Characteristics
This retrospective study was performed in patients 60 years of age or
older with NHL who underwent HDT-ASCT at Memorial Sloan Kettering
Cancer Center (MSKCC) between January 2001 and December 2012. The
institutional review board at MSKCC approved data collection. Data were
primarily extracted from comprehensive chart review and institutional
databases. Pre-HDT-ASCT studies included physical examination; complete
blood count; metabolic panel; chest radiography; computed tomography of
the chest, abdomen and pelvis; ﬂuorine-18-deoxyglucose positron emission
tomography; bone marrow aspiration and biopsy; echocardiography; and
pulmonary function testing. The hematopoietic stem cell transplantation
comorbidity index (HCT-CI) [19] was calculated retrospectively through
chart review of data immediately before HDT-ASCT. The HCT-CI was deﬁned
as low for 0 points, intermediate for 1 or 2 points, and high for >2 points.
Peripheral blood hematopoietic stem cells (HPCs) were collected by leuka-
pheresis after mobilizing cytokines with or without preceding chemo-
therapy priming [20-23]. The minimal acceptable progenitor cell dose was
2  106 CD34þ cells/kg. The day of HPC infusion was considered day 0. Pa-
tients received either ﬁlgrastim 5 mcg/kg/day from day þ5 until neutrophil
recovery (before 2006) or pegﬁlgrastim 6 mg on day þ1 (since 2006) [24].
All patients were hospitalized for HDT-ASCT until engraftment unsupported
by transfusions and adequate gastrointestinal recovery. Engraftment was
deﬁned as sustained neutrophil recovery that is the ﬁrst of 3 consecutive
days with a count  .5  109/L. Patients were kept in single rooms and were
managed clinically according to MSKCC standard guidelines, including
infection prophylaxis.
Conditioning Regimens
HDT varied according to the patient’s diagnosis, remission status, and
comorbidities. One hundred and forty-nine patients (74%) received BEAM
(carmustine 300 mg/m2  1 dose, etoposide 100 to 150 mg/m2 every 12
hours  8 doses, cytarabine 200 mg/m2 every 12 hours  8 doses, and
melphalan 140 mg/m2  1 dose) as their primary HDT regimen. Several
patients also received preceding immunotherapy with accelerated ritux-
imab 375 mg/m2  2 doses (n ¼ 10; 5%) or radio-immunotherapy with
Yttrium-90 ibritumomab tiuxetan (n ¼ 7; 3.5%) or Iodine-131 tositumomab
(n ¼ 5; 2.5%) in addition to BEAM. Patients with central nervous system
lymphoma (CNSL, n ¼ 18; 9%) received thiotepa 250 mg/m2 daily  3 doses,
busulfan 3.2mg/kg daily 3 doses, and cyclophosphamide 60mg/kg daily
2 doses. Other less commonly used conditioning regimens included
melphalan and etoposide (n ¼ 6; 3%); cyclophosphamide and etoposide 
total body irradiation (n ¼ 3; 1.5%); cyclophosphamide, carmustine, and
etoposide (n ¼ 2; 1%), mitoxantrone and melphalan (n ¼ 1; .5%); and rit-
uximab, carmustine, cyclophosphamide, and etoposide (n ¼ 1; .5%). HDT
was not routinely adjusted for body weight or impaired renal function. For
those patients who received involved ﬁeld radiation therapy before HDT-
ASCT, radiation was limited to no more than 2 anatomically involved
lymph node regions and was administered before HDT for disease
measuring at least 5 cm before salvage therapy. Involved ﬁeld radiation
therapy was delivered in 1.5 Gy fractions twice daily to a total dose of 30 Gy
over 10 days [25].
Statistical Methods
Descriptive statistics were used to summarize patient characteristics.
Kaplan-Meier methodology and the log-rank test were used to examine OS
and PFS by patient characteristics. Cumulative incidence functions were
used to estimate the cumulative incidence of progression of disease andtransplantation-related mortality (TRM), with nonrelapse mortality and
progression as competing events, respectively. Analyses were performed in
R statistical software version 2.13.2 (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
Patient demographics are summarized in Table 1. Sixty-
seven percent were men. Of the 202 patients 60 years and
older (median age, 65; range, 60 to 74 years), 90 patients
were ages 60 to 64, 82 were ages 65 to 69, and 30 patients
were 70 or older. Histologies for which patients underwent
HDT-ASCT included diffuse large B cell lymphoma (DLBCL,
n¼ 74, 37%), MCL (n¼ 69, 34%), FL (n¼ 12, 6%), CNSL (n¼ 13,
7%), and TCL (n ¼ 25, 12%). Nine patients (4%) had other NHL
histologies, including chronic lymphocytic leukemia/small
lymphocytic lymphoma (n ¼ 2), marginal zone lymphoma
(n¼ 2), plasmablastic lymphoma (n¼ 1), lymphoplasmacytic
lymphoma (n ¼ 2), T cellerich B cell lymphoma (n ¼ 1), and
blastic plasmacytoid dendritic cell lymphoma (n ¼ 1). HDT-
ASCT in ﬁrst remission was performed in 93 patients (46%),
the majority of which were for MCL (n ¼ 65, 71%). Of the 202
patients, 170 (84%) were in complete remission at the time of
HDT-ASCT. With regards to treatment before HDT-ASCT, 45%
of patients received 1 line of therapy, 48% received 2 lines,
and 7% received more than 2 lines of therapy. One hundred
and eighty-three (91%) patients received anthracycline-
containing combination chemotherapy at some point dur-
ing their treatment course. Of the relapsed or refractory
DLBCL cases (n ¼ 65), 45 (70%) received ifosfamide, carbo-
platin, and etoposide (ICE)ebased and 10 (15%) received
dexamethasone, cytarabine, and cisplatin (DHAP)ebased
salvage therapy, whereas 10 (15%) received other salvage
programs. Of the ﬁrst remission MCL transplantation
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Figure 1. PFS and OS in all patients.
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 2004e20092006patients (n ¼ 65), 47 (72%) received ICE-based sequential
therapy after rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone [26], whereas 15 (23%) received
rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) in combination with cytarabine-
containing programs in either sequence or alternating cy-
cles. The majority of these cases received induction with
either high-dose cytarabine [3] or dexamethasone, cytar-
abine, and cisplatin [5]. Three patients (5%) received other
regimens. Of the TCL ﬁrst remission patients (n ¼ 20), 10
(50%) received CHOP  etoposide and 10 (50%) received
sequential CHOP/ICE.
The median number of HPCs infused was 5.0 106 CD34þ
cells/kg (range, 1.5 to 14.7). The median time to neutrophil
engraftment was 10 days (range, 7 to 16). One patient died
before neutrophil engraftment. Forty-four patients (22%)
were readmitted to the hospital in the ﬁrst 100 days after
HDT-ASCT (range, 16 to 98 days). The majority (n ¼ 30, 68%)
were admitted for infection, 9 (21%) for transplantation-
related toxicity, and 5 (11%) for other causes. With a me-
dian follow-up of 3.6 years (range, .4 to 11.9) for survivors,
PFS and OS at 3 years were 60% (95% conﬁdence interval [CI],
53% to 68%) and 73% (95% CI, 67% to 80%), respectivelyP = .78
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Figure 2. OS (left) an(Figure 1). No difference was found in OS and PFS between
patients older than 65 and those between 60 and 64 years of
age. Similarly, we found no difference in OS and PFS in pa-
tients 70 or older when compared with those between ages
60 and 69 (Figure 2). At 3 years, PFS in patients receiving
upfront transplantationwas 67% comparedwith 54% in those
who received transplantation for relapsed or refractory dis-
ease (P ¼ .03). OS in upfront transplantation was 81%,
compared with 66% in the relapsed or refractory setting (P ¼
.01). Patients with MCL had better outcomes compared with
those with other NHL histologies, with 3-year OS of 89%
versus 65% (P ¼ .002) and PFS of 76% versus 52% (P ¼ .001),
respectively. HCT-CI score was not associated with OS or PFS
(Figure 3).
Overall, 77 patients (38%) progressed (DLBCL [n ¼ 34,
46%], MCL [n¼ 22, 32%], FL [n¼ 4, 33%], primary CNSL [n¼ 1,
8%], TCL [n ¼ 12, 48%], and others [n ¼ 4, 44%]). Median time
to treatment failure was 13.6 months (range, 1.4 to 106).
Incidence of disease progression at 1 year after HDT-ASCT
was 28% (21 of 74) in DLBCL, 6% (4 of 69) in MCL, 17% (2 of
12) in FL, 8% (1 of 13) in primary CNSL, 32% (8 of 25) in TCL,
and 22% (2 of 9) for all other subtypes.
Eight patients experienced TRM within the ﬁrst 100 days
after transplantation. Five died from infections and 3 from
treatment-related organ toxicity. Cumulative incidence of
TRMwas 4% (95% CI, 2% to 7%) at 100 days. This remained the
same at 1 year after HDT-ASCT. High HCT-CI was not asso-
ciated with TRM (Figure 4).
Seventy-six (38%) patients died after HDT-ASCT. The most
common cause of death was progression of disease, which
accounted for 54 deaths (71%). Other deaths were attribut-
able to infections (n ¼ 5), organ toxicity (n ¼ 4), myelodys-
plastic syndrome (MDS) or acute leukemia (AML) (n¼ 4), and
solid tumors (n ¼ 4). Four patients died of unknown causes.
One patient died from graft-versus-host disease after a
subsequent allogeneic stem cell transplantation.
Overall 7 patients (4%) developed secondaryMDS or AML,
at a median of 35 months after HDT-ASCT (range, 6 to 48);
other secondary malignancies (solid tumors) were seen in 9
patients (4.5%) after HDT-ASCT.
Demographics of patients ages 70 or older at time of HDT-
ASCT are summarized in Table 2. In this group, comorbidities
that compose the HCT-CI were present in 73% of patients, the
most common being previous malignancy and pulmonary orP = .77
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Figure 3. OS (left) and PFS (right) according to HCT-CI.
Table 2
Patient Characteristics Age 70 or Above (n ¼ 30)
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 2004e2009 2007cardiac disease. Of the total 30 patients in this age group, 18
are alive, including 4 who experienced disease progression.
Causes of death in the other 12 patients were progression of
disease (n¼ 7), secondary MDS/AML (n¼ 3), secondary solid
tumor (n ¼ 1), and infection (n ¼ 1). The incidence of MDS/
AML in patients ages 70 or older was 10% (n ¼ 3 out of 30
total), whereas its incidence in those 60 to 69 years old was
2% (n ¼ 4 out of 172 total) (P ¼ .07). As stated before, PFS, OS,
and TRM in this age group were not signiﬁcantly different
from patients between 60 and 69 years of age.
DISCUSSION
HDT-ASCT for NHL has not been commonly offered to
elderly patients perhaps due in part to limited data on
feasibility and efﬁcacy of this treatment modality in older
individuals. Given the demonstrable prognostic impact of
HDT-ASCT in younger patients, as previously highlighted by
prospective randomized studies, the omission of HDT-ASCT
based upon age alone could potentially affect survival in
this group. We demonstrate in this study that HDT-ASCT is
safe and effective in selected patients from age 60 to 74 years
and that age alone is not a signiﬁcant risk factor for TRM,0 1 2 3 4
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Figure 4. TRM according to HCT-CI.even in the subgroup of those ages 70 to 74.We observed a 3-
year OS and PFS of 73% and 60%, respectively. Our outcomes
appear similar or favorable, compared with other published
reports on elderly patients with NHL undergoing HDT-ASCT
[16-18]. This is most notable when compared with the
study by Chihara et al. [15] (n ¼ 484) that showed a 2-year
PFS and OS of 48% and 58%, respectively. Other studies are
summarized in Table 3. The varying results in the survival
rate are likely attributable to differences in patient and dis-
ease characteristics, as we included patients who received
HDT-ASCT as consolidation therapy in ﬁrst remission for a
relatively indolent disease (MCL), in contrast to relapsed and
refractory aggressive NHL. Approximately one third of our
patients had MCL, with the majority undergoing HDT-ASCT
in ﬁrst remission. This group had a superior OS and PFS at
3 years compared with those with the other NHL histologies
(OS: 89% versus 65% and PFS: 76% versus 52%). Again, this is
likely attributed to both the natural history of MCL and the
fact that patients receiving consolidation in ﬁrst remissionCharacteristic Value
Gender (male) 25 (83%)
Histology
DLBCL 12 (40%)
CR2, n 8
CR3, n 1
PR, n 3
MCL 8 (27%)
CR1, n 8
FL 4 (13%)
CR2, n 3
CR3, n 1
TCL 3 (10%)
CR1, n 2
PR, n 2
Other NHL 3 (10%)
HCT-CI
Low (0) 8 (27%)
Intermediate (1-2) 3 (10%)
High (>2) 19 (63%)
DLBCL indicates diffuse large B-cell lymphoma;MCL, mantle cell lymphoma;
FL, follicular lymphoma; PCNSL, primary central nervous system lymphoma;
TCL, T-cell lymphoma; NHL, Non-Hodgkin lymphoma; CR, complete
remission; PR, partial remission; HCT-CI, hematopoietic stem cell transplant
comorbidity index.
Data presented are n (%) unless otherwise indicated.
Table 3
Comparative Table of Outcomes of HDT-ASCT in Elderly with NHL
Reference Patients Prep
Regimen
Early TRM
(100 d)
Late TRM
(1 yr)
OS, % PFS, % HCT-CI MDS AML
Jantuen et al. Haematolog 2008, [16] n ¼ 463
DLBCL
Age  60
BEAM
73%
4.4% 8.7% 3 yr
60%
3 yr
51%
Not reported 3 yr: 2.5%.
5 yr: 7.5%.
Jantuen et al. Ann Onco 2012, [18] n ¼ 79
MCL
Age  65
BEAM
72%
3.8% 3.8% 5 yr
61%
5 yr
29%
Not reported Not reported
Hosing et al. Ann Onco 2008, [17] n ¼ 99
NHL
Age  65
BEAM
90%
3% 8%
26 mo
3 yr
61%
3 yr
48%-69%
No effect 8 patients
median 20 mo
Chihara et al. Biol Blood Marrow
Transplant 2014, [15]
n ¼ 484
DLBCL
Age  60
Variable 4.1% 5.9% 2 yr
58%
2 yr
48%
Not reported Not reported
MSKCC data, present study n ¼ 202
NHL
Age  60
BEAM
74%
4% 4% 3 yr
73%
3 yr
60%
No effect 7 (4%) patients
median 35 mo
DLBCL indicates diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; NHL, Non-Hodgkin lymphoma; BEAM, carmustine, etoposide, cytarabine,
melphalan; TRM, transplant-related mortality; OS, overall survival; PFS, progression-free survival; HCT-CI, hematopoietic stem cell transplant comorbidity
index; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia.
P.B. Dahi et al. / Biol Blood Marrow Transplant 20 (2014) 2004e20092008are typically less heavily pretreated. In our study, 93 (46%)
patients received HDT-ASCT as consolidative treatment in
ﬁrst remission. The majority of patients had received 2 or
fewer lines of therapy and were in remission before HTD-
ASCT. Certainly, chemosensitivity before HDT-ASCT carries
the largest prognostic relevance [27,28].
Early TRM rate at day 100 was 4% in our study, which
is comparable to those reported in other earlier series
[13,16-18]. No additional TRM events were noted at 1 year
after HDT-ASCT, likely reﬂecting the immediate and rela-
tively short-term risk of barrier mucocutaneous toxicity in
the neutropenic state after HDT-ASCT. This low rate of TRM
likely reﬂects both patient selection before HDT-ASCT and
ongoing advances in supportive care. Contextually, these
data further highlight the overwhelming majority of treat-
ment failure events being progression of primary NHL.
Interestingly, the incidence of MDS/AML in patients age
70 or older was higher than it was for those between the ages
of 60 and 69 (P ¼ .07). This could be attributed to higher
incidence of MDS/AML with increasing age. Previous studies
reported older age, radiation, and the quantity of pre-
transplantation therapy as risk factors for therapy-related
MDS and AML after HDT-ASCT [29-31]; however, in those
studies, older age was deﬁned as age older than 35 to 40
years. Our study suggests that patients older than 69 may be
at a higher risk for secondary MDS/AML and this may indi-
cate the need for evaluation of bone marrow for early MDS
before stem cell collection.
Within this cohort, we analyzed other clinical character-
istics thatmaypredict adverseoutcomesafter transplantation.
HCT-CI, which derives from physiologic assessment and the
presence of particular comorbidities at the time of trans-
plantation, is a useful tool to predict survival after allogeneic
transplantation [19]. Several retrospective analyses assessed
the role of HCT-CI as a predictor of outcomes in patients un-
dergoing HDT-ASCT [17,32,33]. In our study, although most of
the patients had high HCT-CI scores, this score was not asso-
ciatedwith risk of TRM, norwas it associatedwith eitherOS or
PFS. Our results are consistent with the study by Hosing et al.
[17] (n ¼ 99) reporting no effect of HCT-CI on HDT-ASCT out-
comes in patients older than 65 with relapsed and refractory
NHL. However, we note that the lack of demonstrable prog-
nostic impact of HCT-CI onHDT-ASCToutcomesmay be due to
lack of statistical power with limited patient numbers, ascomparedwith theCenter for International BloodandMarrow
Transplant Research study [33]. Other tools, such as compre-
hensive geriatric assessment, could potentially be utilized to
identify elderly, frail patients at higher risk of post-HDT-ASCT
mortality [34]. We did not incorporate a geriatric assessment
in patient selection.
Our study has a number of limitations. It is retrospective
and conducted in a single center. The small number of pa-
tients included in this study overall, and speciﬁcally in the
group older than 69, could have contributed to the lack of
demonstrable prognostic impact of age and HCT-CI on HDT-
ASCT outcomes in this population. Another important limi-
tation pertains to analyzing transplantation outcomes in a
rather nonhomogeneous cohort of patients, ranging from
those with more indolent histologies who received HDT-
ASCT as consolidation therapy in ﬁrst remission, to those
with other more aggressive NHL subtypes who received
HDT-ASCT after multiple lines of therapy for relapsed and
refractory disease.
In conclusion, within this cohort of elderly patients with
NHL undergoing HDT-ASCT, we demonstrate feasibility and
efﬁcacy with survival comparable to those for younger his-
torical controls [1,2,5,35]. Our data suggest that age alone is
not predictive of HDT-ASCT outcomes and, therefore, should
not be used to preclude HDT-ASCT up to age 74. Although
further prospective investigation is warranted, particularly in
patients older than 74 years of age, our data do not support
routine exclusion of patients based on age or HCT-CI, espe-
cially in clinical settings where clear beneﬁt has been deﬁned
and the vast majority of survival events are secondary to
disease progression [1-6,9,33]. Although we demonstrate
relatively favorable results after HDT-ASCT in elderly pa-
tients, application of this treatment should be carefully
considered individually and reserved for a selected popula-
tion. Further prospective investigation toward identifying a
subset of elderly patients who carry a high risk of treatment-
related morbidity or mortality or of MDS/AML is warranted
with careful consideration toward NHL disease risk and the
potential beneﬁt of HDT-ASCT.
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